# Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Source: https://onco.cc/trials/nct05501665/  
OnCo record `nct05501665` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of carboplatin, fludeoxyglucose F-18 (FDG), nab-paclitaxel, pembrolizumab and other drugs in lung cancer, run by Vanderbilt-Ingram Cancer Center, now recruiting.

## Summary

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer is a phase 1/2, interventional study registered as NCT05501665 by Vanderbilt-Ingram Cancer Center, with a registry enrolment figure of 25 participants, started 2023-05-09 and due to reach its primary completion in 2026-02-01. Interventions recorded: Biospecimen Collection; Carboplatin; Computed Tomography; Fludeoxyglucose F-18; Nab-paclitaxel; Pembrolizumab; Pemetrexed; Positron Emission Tomography; Radiation Therapy; [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan; Ipilimumab; Nivolumab; Cemiplimab; Atezolizumab. Conditions listed: Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage III Lung Cancer. Primary outcome: Incidence of adverse events; Best overall response rate. Lung eligibility wording from the registry: "* • Histologically documented or cytologically confirmed diagnosis of stage IVA or IVB (M1b or M1c) or locally advanced (not eligible for standard of care \[SOC\] chemoradiation) non-small cell lung cancer with evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05501665
- Phase: 1/2
- Setting: SiCARIO (Split Course Adaptive Radioimmunotherapy) for the Treatment of Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Using Biologically-Adaptive Radiotherapy - A Phase I/II Study
- Sponsor: Vanderbilt-Ingram Cancer Center
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT05501665: https://clinicaltrials.gov/study/NCT05501665

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [Fludeoxyglucose F-18 (FDG)](https://onco.cc/drugs/fludeoxyglucose-f18/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05501665.json